MDR TB patients will soon be able to get rid of the disease with less medicines in less time. Research on the new regimen of MDR TB has been started in 10 medical colleges of the country. Trial on the new drug has been started in two medical colleges KGAU Lucknow and Agra Medical College in the state. Patients are expected to receive the new regimen called B-PAL by the end of 2022.
This research has started under the initiative of Indian Council for Medical Research. In the new regimen, instead of six drugs, three drugs, Bedaquiline, Pretomanid, Linezonide are being used. This medicine will be given to the patients only for six months.
Whatever medicines are available till now, they have to be taken for nine months, 11 months and 18 months. The Head of the Department of Respiratory Medicine, KGMU Lucknow, Prof. Suryakant says that continuous work is being done on how to give relief to MDR and XDR patients in less time with less medicines.
Success is also being achieved in this, so far all the new regimen medicines are being given to the patients, the percentage of profit has increased.
Pro. According to Suryakant, Head of the Department of Respiratory Medicine, KGMU, a new era is beginning in the treatment of MDR TB. On the guidelines of ICMR, the university has started testing a new regimen of three drugs. It can be said that the initial results are encouraging. It is too early to talk fully about the results.
Pro. Sudhir Chaudhary, former Head of the Department of Respiratory Medicine, GSVM, says that the new regimen of MDR patients has benefited. To eliminate TB by 2025, it is very important to stop MDR TB, so research is being done on new regimens. New research of ICMR is also in this episode. There will be success in this.